文献リスト

1) Izumi N. Recent advances of radiofrequency ablation for early hepatocellular carcinoma. J Gastroenterol Hepatol. 2011; 26 S1: 115-22

2) N'Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009; 50: 1475-83

3) Rossi S, Ravetta V, Rosa L, et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-tem cohort study. Hepatology. 2011; 53: 136-47

4) Dhanasenkaran R, Khanna V, Kooby DA, et al. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2010; 21: 1197-204

5) Huo TI, Hsu CY, Huang CW, et al. Prognostic prediction across a gradient of total volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterol. 2010; 10: 146

6) Waki K, Aikata H, Katamura Y, et al. Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up. J Gastroenterol Hepatol. 2010; 25: 597-604

7) Tsai MC, Wang JH, Hung CH, et al. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2010; 25: 605-12

8) Beppu T, Sugimoto K, Shiraki K, et al. Clinical significance of tumor markers in detection of recurrent hepatocellular carcinoma after radiofrequency ablation. Int J Mol Med. 2010; 26: 425-33

9) Nouso K, Kobayashi Y, Nakamura S, et al. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol. 2011; 26: 1195-200

10) Dal Bello B, Rosa L, Campanin N, et al. Glutamine synthetase immnunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res. 2010; 16: 2157-66

11) Okuwaki Y, Nakazawa T, Kokubu S, et al. Repeat radiofrequency ablation provides survival benefit in patients with intrahepatoic distant recurrence of hepatiocellular carcinoma. Am J Gastroenterol. 2009; 104: 2747-53

12) Kuroda H, Kasai K, Kakisaka K, et al. Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma. Hepatol Res. 2010; 40: 550-4

13) Kondo Y Shiina S, Tateishi R, et al. Intrahepatic bile duct dilatation after percutaneous radiofrequency ablation for hepatocellular carcinoma: impact on patient's prognosis. Liver Int. 2011; 31; 197-205

14) Imai K, Takai K, Nishigaki Y, et al. Insulin resistance raises the risk for recurrence of stage 1 hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: a prospective, case series study. Hepatol Res. 2010; 40: 376-82

15) Chen TM, Lin CC, Huang PT, et al. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2011; 26: 858-65

16) Goto T, Yoshida H, Tateishi R, et al. Influence of serum HBVDNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatol Int. 2011; 5: 767-73

17) Chuma M, Hige S, Kamiyama T, et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2009; 44: 991-9

18) Ikeda K, Kobayashi M, Seko Y, et al. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence after radical ablation: A retrospective study of hepatitis C virus-related liver cancer. Hepatol Res. 2010; 40: 1168-75

19) Ishikawa T, Michitaka I, Kamimura H, et al. Oral branched-chain amino acid administration improves impaired liver dysfunction after radiofrequency ablation therapy for hepatocellular carcinoma. Hepatogastroenterology. 2009; 56: 1491-5

20) Ishikawa T, Higuchi K, Kubota T, et al. Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for stage I/II hepatocellular carcinoma. Cancer. 2011; 117: 400-5

21) Cho YK, Kim JK, Kim WT, et al. Hepatic resection versus radiofrequency ablation for very early atage hepatocellular carcinoma: a Marcov model analysis. Hepatology. 2010; 51: 1284-90

22) Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010; 252: 903-12

23) Molonari M, Helton S. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhosis individuals not candidates for liver transplantation: a Marcov model decision analysis. Am J Surg. 2009; 198: 396-406

24) Liu JG, Wang YJ, Du Z. Radiofrequency ablation in the treatment of small hepatocellular carcinoma: a meta analysis. World J Gastroenterol. 2010; 21: 3450-6

25) Santambrogio R, Opocher E, Zuin M, et al. Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and Child-Pugh class a liver cirrhosis. Ann Surg Oncol. 2009; 16: 3289-98

26) Kim H, Rhim H, Choi D, et al. Recurrence and treatment pattern in long-term survivors with hepatocellular carcinoma: a comparison between radiofrequency ablation and surgery as a first-line treatment. World J Surg. 2010; 34: 1881-6

27) Kagawa T, Koizumi J, Kojima S, et al. Transarterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010; 116: 3638-44

28) Hung HH, Chiou YY, Hsia CY, et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol. 2011; 9: 79-86

29) Ikeda K, Kobayashi M, Kawamura Y, et al. Stage progression of small hepatocellular carcinoma after therapy: comparisons of radiofrequency ablation and surgery using the Marcov model. Liver Int. 2011; 31: 692-9

30) Guo WX, Zhai B, Lai EC, et al. Percutaneous radiofrequency ablation versus partial hepatectomy for multicentric small hepatocellular carcinomas: a nonrandomized comparative study. World J Surg. 2010; 34: 2671-6

31) Huang J, Hernandez-Alejandro R, Croome KP, et al. Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in Child A cirrhosis- a retrospective study of 1, 061 cases. J Gastrointest Surg. 2011; 15: 311-20

32) Gravante G, Overton J, Sorge R, et al. Radiofrequency ablation versus resection for liver tumors: an evidence-based approach to retrospective comparative studies. J Gastrointest Surg. 2011; 15: 378-87

33) Yun WK, Choi MS, Choi D, et al. Superior long-term outcomes after surgery in child-pugh class a patients with single small hepatocellular carcinoma compared to radiofrequency ablation. Hepatol Int. 2010; 5: 722-9

34) Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation as first-line treatment for small solitaty hepatocellular carcinoma: long-tem results. Eur J Surg Oncol. 2010; 36: 1054-60

35) Cheung TT, Ng KK, Chok KS, et al. Combined resection and radiofrequency ablation for multi-focal hepatocellular carcinoma: prognosis and outcomes. World J Gastroenterol. 2010; 16: 3056-62

36) Kim SR, Imoto S, Nakajima T, et al. Well-differntiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation. Hepatol Int. 2009; 3: 411-5

37) Wakui N, Iida K, Ikehara T, et al. Recurrence incidence of small HCC in cirrhosis patients by ablation versus injection. Hepatogastroenterology. 2010; 57: 195-201

38) Kuang M, Lu MD, Xie XY, et al. Ethanol ablation of hepatocellular carcinoma up to 5. 0 cm by using a multipronged injection needle with high-dose strategy. Radiology. 2009; 253: 552-61

39) Germani G, Pleguezuelo M, Gurusamy K, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. J Hepatol. 2010; 52: 380-8

40) Hsu CY, Huang YH, Choiou YY, et al. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transpl. 2011; 17: 556-66

41) Hiraoka A, Michitaka K, Horiike N, et al. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. J Gastroenetrol Hepatol. 2010; 25: 403-7

42) Takahashi H, Mizuta T, Kawazoe S, et al. Efficacy and safety of radiofrequency ablation for elderly hepatocellular carcinoma. Hepatol Res. 2010; 40: 997-1005

43) Cha J, Rhim H, Lee YS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma: assessment of safety in patients with ascites. Am J Roentgenol. 2009; 193: W424-9

44) Kim JE, Kim YS, Rhim H, et al. Outcomes of patients with hepatocellular carcinoma referred for percutaneous radiofrequency ablation at a tertialy center: Analysis focused on the feasibility with the use of ultrasonography guidance. Eur J Radiol. 2011; 79: e80-4

45) Filippousis P, Sotiropoulou E, Manataki A, et al. Radiofrequency ablation of subcapsular hepatocellular carcinoma: single center experience. Eur J Radiol. 2011; 77: 299-304

46) Kang TW, Rhim H, Lee MW, et al. Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: comparison of effects of thermal protection and therapeutic efficacy. Am J Roentgenol. 2011; 196: 907-13

47) Salama IA, Korayem E, ElAbd A. Laparoscopic ultrasound with radiofrequency ablation of hepatic tumors in cirrotic patients. J Laparoendosc Surg Tech A. 2010; 20: 39-46

48) Panaro F, Piardi T, Audet M, et al. Laparoscopic ultrasound-guided radiofrequency ablation as a bridge to liver transplantation for hepatocellular carcinoma: preliminary results. Transplant Proc. 2010; 42: 1179-81

49) Tesche LJ, Newton KN, Unger J, et al. Efficacy and tolerability of laparoscopic-assisted radiofrequency ablation of hepatocellular carcinoma in patients above 60 years of age. Sur Laparosc Endosc Tech. 2010; 20: 409-9

50) Hirooka M, Kisaka Y, Uehara T, et al. Efficacy of laparoscopic radiofrequency ablation for hepatocellular carcinoma compared to percutaneous radiofrequency ablation with artificial ascites. Dig Endosc. 2009; 21: 82-6

51) Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect referfusion ultrasound imageing, using sonazoid in the management of hepatocellular carcinoma. Oncology. 2010; S1: 40-5

52) Masuzaki R, Shiina S, Tateishi R, et al. Utility of contrast-enhanced ultrasonography with Sonazoid in radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2011; 26: 759-64

53) Ishizaka H, Awata S, Arai H, et al. CT-guided radiofrequency liver tumour ablation: use of a two-step coaxial system with a fine guide needle wire unit for high-risk cases. Br J Radiol. 2010; 83: 1077-9

54) Laspas F, Sotiropoulou E, Mylona S, et al. Computed tomography-guided radiofrequency ablation of hepatocellular carcinoma: treatment efficacy and complications. J Gastrointest Liver Dis. 2009; 18: 323-8

55) Cassera MA, Potter KW, Ujiki MB, et al. Computed tomography(CT)-guided versus laparoscopic radiofrequency ablation: a single-institution comparison of mobidity rates and hospital costs. Surg endosc. 2011; 25: 1088-95

56) Kirikoshi H, Saito S, Yoneda M, et al. Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatol Res. 2009; 39: 553-62

57) Morimoto M, Numata K, Kondou M, te al. Midtem outcomes in patients with intermediate-seized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010; 116: 5452-60

58) Kim JH, Won HJ, Shin YM, et al. Medium-sized (3. 1 – 5. 0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol. 2011; 18: 1624-9

59) Peng ZW, Chen MS, Liang HH, et al. A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol. 2010; 36: 257-63

60) Kim JW, Kim JH, Won HJ, et al. Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency alone. Eur J Radiol. 2011 Feb 24: Epub

61) Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 2010; 30: 741-9

62) Shibata T, Isoda H, Hirokawa Y, et al. Samll hepatocellular carcinoma: is radiofrequency ablation combined with trascatheter arterial chemoembolization more than radiofrequency ablation alone for treatment？ Radiology. 2009; 252: 905-13

63) Kim YS, Lee WJ, Rhim H, et al. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (＞1 and ＜5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. Am J Roentgenol. 2010; 195: 758-65

64) Hwang J, Kim SH, Kim YS, et al. Gadoxetic acid-enhanced MRI versus multiphase multidetector row computed tomography for evaluating the viable hepatocellular carcinomas treated with image-guided tumor therapy. J Magn Reson Imaging. 2010; 32: 629-38

65) Yoon JH, Lee EJ, Cha SS, et al. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomo-graphy in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol. 2010; 21: 348-56

66) Koda M, Tokunaga S, Fujise Y, et al. Assessment of ablative margin after radiofrequency ablation for hepatocellular carcinoma; comparison between magnetic resonance imaging with ferucarbotran and enhanced-CT with iodized oil deposition. Eur J Radiol. 2011 Mar 24; Epub

67) Koda M, Mandai M, Matono T, et al. Assessment of the ablated area after radiofrequency ablation by contrast-enhanced sonography; comparison with virtual sonography with magnetic navigation. Clin Imaging. 2010; 34: 60-4

68) Shiozawa K, Watanabe M, Takayama R, et al. Evaluation of local recurrence after treatment for hepatocellular carcinoma by contrast-enhanced ultrasonography using Sonazoid: comparison with dynamic computed tomography. J Clin Ultrasound. 2010; 38: 182-9

69) Kisaka Y, Hirooka M, Koizumi Y, et al. Contrast-enhanced sonography with abdominal virtual sonography in monitoring radiofrequency ablation of hepatocellular carcinoma. J Clin Ultrasound. 2010; 38: 138-44

70) Zerbini A, Pilli M, Laccabue D, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology. 2010; 138: 1931-42

71) Hiroishi K, Eguchi J, Baba T, et al. Strong CD8(＋) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2010; 45: 451-8

72) Kargozaran H, Wildendorf S, Khatri VP. Radiofrequency- assisted hepatectomy using bipolar inline multichannel radiofrequency device (ILMRD): report of initial clinical experience. Hepatogastroenterology. 2009; 56: 1496-500

73) Meijerink MR, van den Tol P, van Tiborg AA, et al. Radiofreqency ablation of large liver tumours using novel plan-parallel expandable bipolar electrodes: initial clinical experience. Eur J Radiol. 2011; 77: 167-71

74) Fukuda H, Numata K, Nozaki A, et al. Findings of multidetector row computed tomography of HCCs treated by HIFU ablation. Eur J Radiol. 2011 Feb 19; Epub

75) Caspani B, Ierardi AM, Motta F, et al. Samll nodular hepatocellular carcinoma treated by laser thermal ablation in high risk locations: preliminary results. Eur Radiol. 2010; 20: 2286-92

76) Combs SE, Habermehl D, Ganten T, et al. Phase I study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trila. BMC Cancer. 2011; 11: 67

77) Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres; a comprehensive literature review. J Vasc Interv Radiol. 2009; 20: 1121-30

78) Matsui O, Miyayama S, Sanada J, et al. Interventinal oncology: new opitions for interstitial treatment and intravascular approaches: superselective TACE using iodized oil for HCC: rationale, technique and outcome. J Hepatobilliary Pancreat Sci. 2010; 17: 407-9

79) Bargellini I, Sacco R, Bozzi M, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study. Eur J Radiol. 2011 Apr 3; Epub

80) Mirici-Cappa F, Gramenzi A, Santi V, et al. Treatment for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut. 2010; 59: 387-96

81) Carr BI, Irish W, Federle MP. Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis. Hepatogastroenterology. 2010; 57: 1375-81

82) Olivo M, Valenza F, Buccelato A, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors. Dig Liver Dis. 2010: 42: 515-9

83) Woo HY, Jang JW, Choi JY, et al. Tumor doubling time after initial response to transarterial chemoembolization in patients with hepatocellular carcinoma. Scand J Gastroenterol. 2010; 45: 332-9

84) Golfieri R, Cappeli A, Cucchetti A, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (＜5 cm) hepatocellular carcinomas. Hepatology. 2011; 53: 1580-9

85) Kloeckner R, Otto G, Biesterfeld S, et al. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010; 33: 532-40

86) Bargellini I, Vignali C, Cioni R, et al. Hepatocelllar carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria-selection parameter for liver transplantation. Radiology. 2010; 255: 289-300

87) Takayasu K, Arii S, Ikai I, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. Am J Roentgenol. 2010; 194: 830-7

88) Okusaka T, Kasugai H, Shioyama Y, et al. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2009; 51: 1030-6

89) Gomes AS, Rosove MH, Rosen PJ, et al. Tripple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patients. Am J Roentgenol. 2009; 193: 1665-71

90) Moriguchi M, Takayama T, Nakamura M, et al. Phase I/II study of a fine-powder formulation of cisplatin for transcatheter arterial chemoembolization in hepatocellular carcinoma. Hepatol Res. 2010; 40: 369-75

91) Yamanaka K, Hatano E, Narita M, et al. Comparative study of cisplatin and epirubicin in transarterial chemoembolization for hepatocellular carcinoma. Hepatol Res. 2011; 41: 303-9

92) Kasai K, Ushio A, Sawara K, et al. Transarterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol. 2010; 16: 3437-44

93) Maeda N, Osuga K, Higashihara H, et al. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresectable to chemoembolization with epirubicin-lipiodol emulsion. Cardiovasc Intervent Radiol. 2011 Jan 4; Epub

94) Lin CT, Hsu KF, Chen TW, et al. Comparing hepatic resection and transarterial chemoembolization for Barcelone Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice？ World J Surg. 2010; 34: 2155-61

95) Hsu KF, Chu CH, Chan DC, et al. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class A liver function. Eur J Radiol. 2011 Mar 2; Epub

96) Kim JM, Know CH, Joh JW, et al. Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation？ Transplant Proc. 2010; 42: 821-4

97) Zhong JH, Li LQ. Postoperative adjuvant trans-arterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res. 2010; 40: 943-53

98) Dufour JF, Hoppe H, Heim MH, et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist. 2010; 15: 1198-204

99) Reyes DK, Vossen JA, Kamel IR, et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009; 15: 526-32

100) Carter S, Martin RC. Drug-eluting bead therapy in primary and metastatic disease of the liver. HPB. 2009; 11: 541-50

101) Wiggermann P, Sieron D, Brosche C, et al. Transarterial chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE). Med Sci Monit. 2011; 17: 189-95

102) Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010; 33: 41-52

103) Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with beadblock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010; 33: 541-51

104) Moschouris H, Malagari K, Papadaki MG, et al. Contrast-enhanced ultrasonography of hepatocellular carcinoma after chemoembolization using drug-eluting beads: a pilot study focused on sustained tumor necrosis. Cardiovasc Intervent Radiol. 2010; 33: 1022-7

105) Carr BI, Kondragunta V, Buch SC, et al. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010; 116: 1305-14

106) Chen X, Lingala S, Khoobyari S, et al. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol. 2011; 55: 838-45

107) Kim JH, Yoon HK, Ko GY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter chemoembolization. Radiology. 2010; 255: 270-7

108) Tsuchiya K, Komuta M, Yasui Y, et al. Expression of keratin19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology. 2011; 80: 278-88

109) Arzumanyan A, Friedman T, Ng IO, et al. Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells？ Cancer Res. 2011; 71: 3701-8

110) Chen KF, Tai WT, Liu TH, et al. Sorafenib overcomes TRAIL resistance pf hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res. 2010; 16: 5189-99

111) Tai WT, Cheng AL, Shiau CW, et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol. 2011; 55: 1041-8

112) Chen YL, Lv J, Ye XL, et al. Sorafenib inhibits transforming growth factor β1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology. 2011; 53: 1708-18

113) Kim HY, Park JW, Nam BH, et al. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. J Gastroenterol Hepatol. 2011; 10: 1440

114) Morimoto M, Numata K, Kondo M, et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res. 2011; 41: 296-302

115) Spira D, Fenchel M, Lauer UM, et al. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol, 2011; 18: 89-96

116) Kim MJ, Choi JL, Lee JS, et al. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2011; 26: 1201-6

117) Lencioni RLlovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30: 52-60

118) Shao YY, Lin ZZ, Hsu C, et al. Early alpha-fetoprotein response predicts treatment efficacy of angiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010; 116: 4590-6

119) Kim JE, Ryoo BY, Ryu MH, et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol. 2011 Mar 29; Epub

120) Ogasawara S, Kanai F, Obi S, et al. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int. 2011; 5: 850-6

121) Coriat R, Gouya H, Mir O, et al. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS One. 2011; 6: 16978

122) Mertens JC, Martin IV, Schmitt J, et al. Multi-kinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals. Eur J Radiol. 2011 May 16; Epub

123) Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010; 304: 2154-60

124) Hoffmann K, Franz C, Xiao Z, et al. Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma. Anticancer Res. 2010; 30: 4503-8

125) Dufour JF, Hoppe H, Heim MH, et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results od a phase 1 study. Oncologist. 2010; 15: 1198-204

126) Cabrera R, Pannu DS, Caridi J, et al. The combination of sorefenib with transarterial chemoembolization for hepatocellular carcinoma. Aliment Pharmacol Ther. 2011; 34: 205-13

127) Hikita H, Takehara T, Shimizu S, et al. The Bcl-xL inhibitor, ABT-737, efficiently induces apotosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology. 2010; 52: 1310-21

128) Fiume L, Vettaino M, Manerba M, et al. Inhibition of lactic dehydrogenase as a way to increase the antiproliferative effect of multi-targeted kinase inhibitors. Pharmacol Res. 2011; 63: 328-34

129) Wei G, Wang M, Hyslop T, et al. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer. 2010; 127: 2949-58

130) Caraglia M, Giuberti G, Marra M, et al. Oxidative stress and ERK 1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2011; Apr 28: 2: e150

131) Hsu CY, Shen YC, Yu CW, et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegaful/uracil. J Hepatol. 2011; 55: 858-65

132) Tang TC, Man S, Xu P, et al. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia. 2010; 12: 928-40

133) Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011; 140: 1410-26

134) Santoro A, Pressiani T, Citterio G, et al. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer. 2010; 103: 837-44

135) Worns MA, Schuchmann M, Duber C, et al. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology. 2010; 79: 85-92

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp